Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology CongressPrinceton, NJ and TOKYO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET-SHUTTLE trial of rocatinlimab, an investigational T-cell rebalancing therapy, will be presented as a late breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025. This trial assessed the efficacy and safety of rocatinlimab every 4 weeks in combination with topical corticosteroids and/or topical calcineurin inhibitors in adults with moderate-to-severe atopic dermatitis (AD).
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic DermatitisTHOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (
NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD).
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare ProvidersFirst-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary Syndrome
